Molecular structure of human galactokinase - Implications for type II galactosemia

被引:95
作者
Thoden, JB
Timson, DJ
Reece, RJ
Holden, HM
机构
[1] Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England
[2] Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA
[3] Queens Univ Belfast, Sch Biol & Biochem, Ctr Med Biol, Belfast BT9 7BL, Antrim, North Ireland
关键词
D O I
10.1074/jbc.M412916200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Galactokinase functions in the Leloir pathway for galactose metabolism by catalyzing the MgATP- dependent phosphorylation of the C-1 hydroxyl group of alpha-D-galactose. The enzyme is known to belong to the GHMP superfamily of small molecule kinases and has attracted significant research attention for well over 40 years. Approximately 20 mutations have now been identified in human galactokinase, which result in the diseased state referred to as Type II galactosemia. Here we report the three-dimensional architecture of human galactokinase with bound alpha-D-galactose and Mg- AMPPNP. The overall fold of the molecule can be described in terms of two domains with the active site wedged between them. The N- terminal domain is dominated by a six- stranded mixed beta-sheet whereas the C-terminal motif contains six alpha-helices and two layers of anti-parallel beta-sheet. Those residues specifically involved in sugar binding include Arg(37), Glu(43), His(44), Asp(46), Gly(183), Asp(186), and Tyr(236). The C-1 hydroxyl group of alpha-D-galactose sits within 3.3 Angstrom of the gamma-phosphorus of the nucleotide and 3.4 Angstrom of the guanidinium group of Arg37. The carboxylate side chain of Asp186 lies within similar to 3.2 Angstrom of the C-2 hydroxyl group of alpha-D-galactose and the guanidinium group of Arg37. Both Arg37 and Asp186 are strictly conserved among both prokaryotic and eukaryotic galactokinases. In addition to providing molecular insight into the active site geometry of the enzyme, the model also provides a structural framework upon which to more fully understand the consequences of the those mutations known to give rise to Type II galactosemia.
引用
收藏
页码:9662 / 9670
页数:9
相关论文
共 46 条
[1]   A mouse model of galactose-induced cataracts [J].
Ai, YJ ;
Zheng, Z ;
O'Brien-Jenkins, A ;
Bernard, DJ ;
Wynshaw-Boris, T ;
Ning, C ;
Reynolds, R ;
Segal, S ;
Huang, K ;
Stambolian, D .
HUMAN MOLECULAR GENETICS, 2000, 9 (12) :1821-1827
[2]   Molecular characterization of galactokinase deficiency in Japanese patients [J].
Asada, M ;
Okano, Y ;
Imamura, T ;
Suyama, I ;
Hase, Y ;
Isshiki, G .
JOURNAL OF HUMAN GENETICS, 1999, 44 (06) :377-382
[3]  
BORK P, 1993, PROTEIN SCI, V2, P31
[4]  
Bosch AM, 2002, J INHERIT METAB DIS, V25, P629, DOI 10.1023/A:1022875629436
[5]  
CAPUTTO R, 1949, J BIOL CHEM, V179, P497
[6]  
CAPUTTO R, 1950, J BIOL CHEM, V184, P333
[7]  
CORNISHBOWDEN A, 2004, FUNDAMENTALS ENZYME, P209
[8]   GALACTOKINASE OF VICIA-FABA SEEDS [J].
DEY, PM .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1983, 136 (01) :155-159
[9]   POLYOL ACCUMULATION IN GALACTOSEMIC AND DIABETIC RATS - CONTROL BY AN ALDOSE REDUCTASE INHIBITOR [J].
DVORNIK, D ;
SIMARDDU.N ;
KRAMI, M ;
SESTANJ, K ;
GABBAY, KH ;
KINOSHITA, JH ;
VARMA, SD ;
MEROLA, LO .
SCIENCE, 1973, 182 (4117) :1146-1148
[10]   The Leloir pathway: A mechanistic imperative for three enzymes to change the stereochemical configuration of a single carbon in galactose [J].
Frey, PA .
FASEB JOURNAL, 1996, 10 (04) :461-470